Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JAMA ginkgo debate

This article was originally published in The Tan Sheet

Executive Summary

"Outcome trials should use cognitive tests that are sensitive to ginkgo's pharmacologic mode of action in the brain," say Pradeep Nathan, PhD, et al., Swinburne University of Technology, Australia, in Feb. 5 JAMA. Letter addresses recent study by Solomon et al. which found ginkgo caused no cognitive function improvement in healthy adults (1"The Tan Sheet" Aug. 26, 2002, p. 14). Nathan et al. suggest the selection of tests by Solomon et al. "may not be suitable to outcome studies of complementary therapies such as ginkgo, which generally produce only a mild to moderate benefit with continued use." Five letters appearing in JAMA challenge the study's blinding, focus on healthy individuals. Solomon et al. maintain their trial addressed manufacturer's claims, did not intend to take on herb's effects on impaired population...

You may also be interested in...



Ginkgo Study Shows “No Measurable Benefit” For Memory, Cognition

Daily doses of ginkgo biloba for six weeks resulted in "no significant difference for any outcome measure" versus placebo in approximately 200 adults over age 60 with healthy cognitive function in a study published in the Aug. 21 Journal of the American Medical Association.

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel